Forward agenda is conversion work: management's own stated priorities are about turning already-secured growth into resu
The model's full reasoning — Q1 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: On this call, when management describes what the company is focused on over the coming quarters — its own stated priorities, tasks, and to-do list — is that forward agenda substantially about CONVERTING GROWTH THE COMPANY HAS ALREADY SECURED into delivered results, AND does management convey that the reported results do not yet meaningfully reflect that secured growth? We need to check both halves. First, what is the forward agenda? The company has two main programs: CUDC-907 (Phase 2 trial ongoing) and CA170 (expected to enter clinic this quarter). Also Erivedge royalties. Management talks about CUDC-907: Phase 2 trial ongoing, enrolling patients with MYC alterations. That is executing on an ongoing trial. But is that "converting growth already secured"? The trial is already launched, but the results are not yet delivered. However, the question is about "growth the company has already secured" - meaning business, orders, contracts, etc. For a biotech, it might be about clinical trials that are already underway, but the revenue or results are not yet realized. But the question specifically says "delivering or fulfilling orders, contracts, awards, or programs already won; ramping, opening, commissioning, or loading a facility, capacity, product, location, or capability already built or recently launched; onboarding, installing, enrolling, or scaling customers or partners already signed; hiring, training, producing, stocking, or sequencing specifically to serve identified business already in hand or already arriving." That seems to fit clinical trials? Possibly. But also, the company has a collaboration with Aurigene, and they have licensed rights. They are developing CA170, which is expected to enter clinic. That is not yet secured growth; it's still in development. The forward agenda: They are running Phase 2 for CUDC-907, they are about to start Phase 1 for CA170, they are also looking at diagnostic capabilities. They are also monitoring Erivedge studies by Roche. Is that "conversion work" or "pursuit work"? The Phase 2 trial is already ongoing, so they are executing on a program already started. But is that "growth already secured"? The growth would be eventual revenue from a drug, but that is not secured.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| EFXT | Enerflex Ltd. | Q3 2023 | 2023-11-09 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
EVGO · Q2 2022 → YESThe question is about whether management's forward agenda is about converting already secured growth into results, and if the reported results don't yet reflect that growth. YES The forward agenda centers on converting already-secured growth: the Pilot-GM eXtend deal (up to 2,000 stalls + 500 locations) is described as recently announced and exceeding IRR hurdles, with EVgo procuring, constructing, operating, and maintaining the assets on a capital-light basis; the 2022 guidance is affirmed and tracked, with heavier second-half loads explicitly tied to PFJ and fleet contractual revenues kicking in Q3/Q4 (some already baked into forecasts after late-2021 negotiations); current stall counts (2,397 in operation/under construction, 3,669 pipeline) and throughput explicitly exclude the 2,000-stall Pilot contribution; Delta supply agreement covers the first phase of the PFJ deal through 2026; and execution themes include ramping stalls, commissioning, fleet onboarding, and regulatory credit recognition tied to these committed contracts. The reported Q2 results ($9.1M revenue, 10.
BRBR · Q4 2023 → YESThe question is: On this call, when management describes what the company is focused on over the coming quarters — its own stated priorities, tasks, and to-do list — is that forward agenda substantial...YES The forward agenda centers on converting already-secured growth by ramping production (17% growth in fiscal '23, 20%+ planned for '24 via new co-mans and Michael Foods startup in December), restarting promotions and marketing once supply allows, and scaling the transformed co-man network to fulfill committed demand — all while noting tight supply dynamics persisting through most of fiscal '24. Management explicitly conveys that the reported FY '23 results (22% sales growth, 25% EBITDA growth) reflect only a portion of the secured trajectory, with the bulk of new capacity contributions and promotional lift still ahead in fiscal '24, treating 10-15% sales and 6-15% EBITDA guidance as the meaningful next step rather than a routine continuation.
EFXT · Q3 2023 → YESThe question is: Does management describe their focus over coming quarters as converting already secured growth into delivered results, AND do they convey that reported results don't yet meaningfully ...YES The transcript shows management's forward agenda centers on converting secured growth: executing on the $1.6 billion Engineered Systems backlog for 2024 revenue visibility, realizing remaining USD 60 million synergies from Exterran integration, consolidating facilities, and prioritizing debt reduction plus operational efficiency. They describe this as turning already-committed 2024 activity into delivered results, with the backlog providing "strong visibility into revenue generation and business activity levels for 2024" and embedded margins in line with mid-teens targets.